Early Bird Prime for March 1, 2026

Novo Nordisk $NVO ( ▼ 0.45% ) is the Danish pharmaceutical giant that’s been in a rough place lately. The stock price is down 58.69% over the past year.

Let's address the elephant in the room: Novo Nordisk's next-gen weight-loss drug (CagriSema) didn't exactly pass its trial with flying colors. Combine that with fierce competition and pricing pressures in the U.S., and you've got a recipe for a stock that's been on a diet of its own by shedding value fast.

This past week, Novo Nordisk announced plans to slash the monthly list prices of its obesity and diabetes drugs by up to 50% starting in 2027. While this move might compress unit economics, it could also open the floodgates to a much larger insured population.

Despite the current stormy weather, Novo Nordisk's fundamentals remain strong. The company still commands a leading share in the GLP-1 market, a multi-hundred-billion-dollar global category in obesity treatment. With chronic use and a large unmet need, demand for these drugs is durable. And let's not forget the long-term addressable market.

Should you buy Novo Nordisk's stock right now in 2026, or should you avoid it? Here’s the answer…

logo

Subscribe to Early Bird Prime to read the rest.

Become a paying subscriber of Early Bird Prime to get access to this post and other subscriber-only content.

Upgrade

A subscription gets you:

  • Expert analysis on the best stocks.
  • Stock price predictions based on machine learning.
  • Investing picks and recommendations.
  • Advertisement-free.

Early Bird